Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2- negative locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole

Jeitler K, Semlitsch T, Nachtnebel A, von Minckwitz G

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation
Jeitler K, Semlitsch T, Nachtnebel A, von Minckwitz G. Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2- negative locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole. Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). Horizon Scanning in Oncology Nr. 32. 2012

Final publication URL
http://eprints.hta.lbg.ac.at/977/1/DSD_ HSO_ Nr.32.pdf

Indexing Status
Subject indexing assigned by CRD

MeSH
Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Females; Postmenopause

Language Published
English

Country of organisation
Austria

English summary
An English language summary is available.

Address for correspondence
Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99 Email: anna.nachtnebel@hta.lbg.ac.at

AccessionNumber
32012000791

Date abstract record published
18/10/2012